Core Insights - The company, Jinfang Pharmaceutical-B (02595), conducted an IPO from September 11 to 16, raising significant interest with a subscription amount of HKD 349.85 billion, resulting in an oversubscription rate of 2,210 times for the public offering portion [1] - The company plans to issue 77.6 million H-shares at a price of HKD 20.39 per share, aiming to raise HKD 1.58 billion, with the shares expected to be listed in Hong Kong on September 19 [1] - Jinfang Pharmaceutical focuses on developing new treatment solutions for oncology, autoimmune, and inflammatory diseases, with a product pipeline that includes eight candidate products, five of which are in clinical development [1][2] Financial Details - The net proceeds from the IPO will be allocated as follows: approximately 33% for the clinical development of core product GFH925, about 38% for core product GFH375, around 19% for the development of other candidates in the pipeline, and about 10% for working capital and general corporate purposes [2] Product Pipeline - Core product GFH925 (fulzerasib, marketed as Daberet®) has been commercially approved in China for the treatment of advanced non-small cell lung cancer (NSCLC) and is currently undergoing Phase II trials in the EU [1] - Another core product, GFH375, is an oral small molecule inhibitor targeting KRAS G12D mutations, with ongoing Phase I/II clinical trials in China for patients with advanced solid tumors carrying this mutation [2]
新股消息 | 劲方医药-B(02595)孖展认购金额逾3498亿港元 超购2210倍